Decellularized dermis allograft for the treatment of venous leg ulceration: the DAVE RCT - Summary - MDSpire

Decellularized dermis allograft for the treatment of venous leg ulceration: the DAVE RCT

  • By

  • Sarah Onida

  • Matthew Tan

  • Valeria Balan

  • Francine Heatley

  • Sarrah Peerbux

  • Layla Bolton-Saghdaoui

  • Tristan Lane

  • David Epstein

  • Manjit Gohel

  • John Norrie

  • Robert Lee

  • Richard Lomas

  • Alun H Davies

  • February 17, 2025

  • 0 min

Share

Objective:

To determine the effectiveness, safety, and cost-effectiveness of decellularized dermis (DCD) allografts as an adjunct treatment for venous leg ulcers (VLUs) in patients aged 18 years and older.

Key Findings:
  • Healing rates were 5.7% in the DCD group and 15.2% in the control group (p-value needed).
  • No significant differences were found in secondary outcomes, including ulcer area change and quality of life.
  • The trial was terminated early due to lower-than-expected healing rates.
Interpretation:

DCD allografts did not improve healing rates for VLUs compared to standard care, and the small sample size limits the ability to draw definitive conclusions; further investigation is warranted.

Limitations:
  • Small sample size limited the statistical power of the study, potentially skewing results.
  • Early termination of the trial may have affected the outcomes, necessitating caution in interpretation.
Conclusion:

DCD allografts did not demonstrate improved healing rates for VLUs, and further research is needed to explore their potential benefits or harms, particularly in larger cohorts.

Original Source(s)

Related Content